---
document_datetime: 2025-12-08 11:44:36
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/symkevi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: symkevi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9974712
conversion_datetime: 2025-12-28 14:55:48.145658
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Symkevi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 24/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000313655   |
|---------------------|

<div style=\"page-break-after: always\"></div>

|                            | responsible do not include batch release - Accepted B.II.e.6 Change in any part of the (primary) packaging material not in contact with the finished product formulation (such as colour of flip-off caps, colour code rings on ampoules, change of needle shield (different plastic used)) - B.II.e.6.b Change that does not affect the product information - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             |           |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------|
| PSUR / EMA/PSUR/0000269024 | - - In view of available data on cases of liver failure reported in patients both with and without pre-existing liver disease for elexacaftor / tezacaftor / ivacaftor (ELX/TEZ/IVA) and in the context of updates made to the product information for ELX/TEZ/IVA, given the very serious nature of the events in question, the PRAC considers that the product information of products containing tezacaftor / ivacaftor should be amended accordingly. In view of available data on anxiety and insomnia from post-marketing reports including in some cases positive de-challenge, the PRAC considers a causal relationship between tezacaftor / ivacaftor and anxiety and insomnia is at least a reasonable possibility. The PRAC concluded that the product information of products containing tezacaftor | 18/09/2025 | 17/11/2025 | SmPC and PL | Variation |

<div style=\"page-break-after: always\"></div>

| / ivacaftor should be amended accordingly.   |
|----------------------------------------------|